AXSM Quote, Financials, Valuation and Earnings

BioVie has a net margin of -63.08% compared to Axsome Therapeutics's net margin of --. Axsome Therapeutics's return on equity of -244.32% beat BioVie's return on equity of --.

Axsome Therapeutics has a consensus price target of $172.35, signalling upside risk potential of 74.34%. On the other hand BioVie has an analysts' consensus of $5.50 which suggests that it could grow by 609.68%. Given that BioVie has higher upside potential than Axsome Therapeutics, analysts believe BioVie is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison BioVie has a beta of 1.270, suggesting its more volatile than the S&P 500 by 26.987%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioVie offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. BioVie pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than BioVie quarterly revenues of --. Axsome Therapeutics's net income of -$74.9M is lower than BioVie's net income of -$7.1M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while BioVie's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.28x versus -- for BioVie. Usually stocks with elevated PS ratios are considered overvalued.

Phathom Pharmaceuticals has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -250.98%. Axsome Therapeutics's return on equity of -244.32% beat Phathom Pharmaceuticals's return on equity of --.

Axsome Therapeutics has a consensus price target of $172.35, signalling upside risk potential of 74.34%. On the other hand Phathom Pharmaceuticals has an analysts' consensus of $21.13 which suggests that it could grow by 332.89%. Given that Phathom Pharmaceuticals has higher upside potential than Axsome Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Phathom Pharmaceuticals has a beta of 0.351, suggesting its less volatile than the S&P 500 by 64.87%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Phathom Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than Phathom Pharmaceuticals quarterly revenues of $29.7M. Axsome Therapeutics's net income of -$74.9M is lower than Phathom Pharmaceuticals's net income of -$74.5M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Phathom Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.28x versus 5.58x for Phathom Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -103.5%. Axsome Therapeutics's return on equity of -244.32% beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Axsome Therapeutics has a consensus price target of $172.35, signalling upside risk potential of 74.34%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $75.25 which suggests that it could grow by 60.28%. Given that Axsome Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Axsome Therapeutics is more attractive than Rhythm Pharmaceuticals.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.321, suggesting its more volatile than the S&P 500 by 132.096%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Axsome Therapeutics's net income of -$74.9M is lower than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.28x versus 22.01x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -125.59%. Axsome Therapeutics's return on equity of -244.32% beat SpringWorks Therapeutics's return on equity of -46.69%.

Axsome Therapeutics has a consensus price target of $172.35, signalling upside risk potential of 74.34%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 86.43%. Given that SpringWorks Therapeutics has higher upside potential than Axsome Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than SpringWorks Therapeutics quarterly revenues of $61.5M. Axsome Therapeutics's net income of -$74.9M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 12.28x versus 15.13x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.